None listed
Conditions
Interventions
Intervention1: TRC041266 Powder: TRC041266 Powder 500 mg (equivalent to TRC4186) in fasting condition
Intervention2: TRC041266 Powder: TRC041266 Powder 500 mg (equivalent to TRC4186) with water in fed
Sponsors
Torrent Pharamceutical Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Male and/or female subjects aged 18-65 years (both inclusive). 2.Volunteer with BMI of 18.5-30 kg/m2 (inclusive both) with minimum weight of 50 kg. 3.Volunteer willing to provide written informed consent. 4.Ability to adhere to the study restrictions and assessments schedule
Exclusion criteria
Exclusion criteria: 1. Inability to communicate or co-operate. 2. History of angina, myocardial infarction (MI) or stroke within last 3 months prior to screening. 3. Volunteers suffering from any chronic illness such as arthritis, asthma etc. 4. History of pre-existing bleeding disorder. 5. Clinically relevant abnormal physical findings at the screening examination, which would interfere with the objectives of the study. 6. Clinically significant abnormalities in the results of the clinical laboratory tests (at screening or check-in day (i.e. Day-0)). 7. Clinically significant abnormal ECG (at screening), 2D Echo or Chest X-ray. 8. Pregnant or lactating women or female subjects who are of childbearing potential and who are neither surgically sterilized nor willing to use reliable contraceptive methods {i) bilateral tubal occlusion; ii) vasectomised partner and iii) sexual abstinence iv) barrier method of contraception} and/or female volunteer with positive urine pregnancy test. 9. Smokers who are unable to stop tobacco consumption during each study period, or smokers who smokes >10 cigarettes (or equivalent) per Day during last 3 months prior to Day 1. 10. Positive for HIV, HCV and HbsAg. 11. History of significant blood loss due to any reason, including blood donation in the past 3 months; or the total blood loss in the last 3 months, including for this study, exceeds 450 ml. 12. Participation in any study within past 3 months 13. Addiction to alcohol or history of alcohol or drug abuse 14. Intake of hepatic microsomal enzyme inducer/inhibitor drugs in the period within 3 months prior to the first dose of study drug 15. History of consumption of prescribed medication since last 14 days or OTC medication/ herbal remedies since last 7 days before beginning of the study. 16. Volunteer found to be positive for breath alcohol test. 17. History of malignancy 18. Volunteer found to be positive for opiate, tetrahydrocannabinoid, amphetamine, barbiturates, benzodiazepines, cocaine based on urine test. 19. Systolic blood pressure less than 100 mmHg or more than 139 mmHg and diastolic blood pressure less than 60 mmHg or more than 89 mmHg. 20. Pulse rate less than 60/minute or more than 100/minute. 21. Oral temperature less than 95°F or more than 98.9°F. 22. Respiratory rate less than 10/minute or more than 20/minute. 23. History of hypersensitivity reaction/allergy to the investigational product or any drug chemically similar to the drug under investigation or any of the excipients. 24. Recent History of kidney or liver dysfunction. 25. Volunteers suffering from any psychiatric (acute or chronic) disorder. 26. Existence of any surgical or medical condition, which, in the judgment of the chief investigator and/or clinical investigator/physician, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of volunteers 27. Volunteers with left ventricular ejection fraction (LVEF) < 55%
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To compare the pharmacokinetics of TRC041266 powder with TRC4186 tablet 2. To evaluate the effect of food on the pharmacokinetics of TRC041266 PowderTimepoint: Pre-dose, and at 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 8.00, 12.00, 24.00, 36.00 and 48.00 hours post dose | — |
Secondary
| Measure | Time frame |
|---|---|
| I. To evaluate the safety and tolerability of TRC041266 Powder in healthy human subjects. II. To study the impact of drug administration by means of comparing bioavailability of TRC041266 in fasting condition while administering it with water and with low fat milk.Timepoint: Vital signs : At enrolment, pre-dose, 1.00, 3.00, 7.00 and 24.00 hours post dose, discharge, post study safety evaluation. Physical examination : Enrolment, at discharge, post study follow up. Well-being of subject: Pre-dose, 1.00, 3.00, 7.00 and 24.00 hours post-dose. ECG measurement: Pre-dose, 2.00, 4.00, 8.00, 24.00 hours post dose, discharge, at post study follow up. Clinical Laboratory Tests: Pre (Screening), enrolment, check-out,Post Study safety evaluation. | — |
Countries
India
Contacts
Public ContactDr Sanjay Sharma
Torrent Pharmaceuticals Ltd
Outcome results
None listed